Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme

Abstract

PURPOSE Evaluation of 1-year safety profile of intravitreal ranibizumab 0.5 mg in neovascular age-related macular degeneration (NV-AMD) within routine clinical practice. METHODS The LUMINOUS programme comprises a prospective observational study assessing ranibizumab 'real-world' safety and clinical effectiveness across licensed indications worldwide and… (More)
DOI: 10.1136/bjophthalmol-2013-303232

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Holz2013SafetyOR, title={Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme}, author={Frank G. Holz and Francesco Bandello and Mark C. Gillies and Paul Mitchell and Aaron F Osborne and Tom G Sheidow and Eric H. Souied and Marta S. Figueroa and Christopher S Brand and Adrian H.C. Koh and Ursula M Schmidt-Erfurth and Namrata Sharma and Steve Winyard}, booktitle={The British journal of ophthalmology}, year={2013} }